PropertyValue
?:abstract
  • In an era of several therapeutic options available, optimal treatment sequencing is crucial to providing patients the most effective therapy and promoting quality of life. In clear cell renal cell carcinoma, a combination approach with an immunotherapy backbone, such as nivolumab/ipilimumab or axitinib/pembrolizumab, has a key role in the first-line setting. Safety and activity data support the transition to single-agent targeted therapies in the second-line setting. Nivolumab monotherapy possesses clinical and mechanistic rationale as a second-line therapeutic option for patients treated with targeted therapies in the first-line setting. Gene expression models are being generated from large prospective clinical trial data sets.
is ?:annotates of
?:creator
?:doi
  • 10.1016/j.ucl.2020.04.008
?:doi
?:journal
  • The_Urologic_clinics_of_North_America
?:license
  • unk
?:pmid
?:pmid
  • 32600533.0
?:publication_isRelatedTo_Disease
?:source
  • Medline
?:title
  • Sequencing Therapies for Metastatic Renal Cell Carcinoma.
?:type
?:year
  • 2020-08-01

Metadata

Anon_0  
expand all